Keywords: genentech, shares, dip, after, stroke, warning, predicted

Genentech shares dip 1.5% after stroke warning on predicted blockbuster Lucentis

Article | 05 February 2007

Print This

US biotehcnology firm Genentech says that its new wet age-related macular degeneration drug Lucentis (ranibizumab) might raise the risk of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in